These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

162 related items for PubMed ID: 22419369

  • 1. The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis.
    Zhang L, Li L, Yang M, Xu K, Boden G, Yang G.
    Osteoporos Int; 2013 Mar; 24(3):1107-12. PubMed ID: 22419369
    [Abstract] [Full Text] [Related]

  • 2. Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China.
    Li Y, Xuan M, Wang B, Yang J, Zhang H, Zhang XZ, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Liu ZM, Li CJ, Wu TF, Sheng ZY, Li PQ, Tong JC.
    Chin Med J (Engl); 2013 Feb; 126(3):457-63. PubMed ID: 23422107
    [Abstract] [Full Text] [Related]

  • 3. The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis.
    Zhang L, Yang M, Liu D, Guo C, Li L, Yang G.
    Exp Clin Endocrinol Diabetes; 2012 Jun; 120(6):361-6. PubMed ID: 22639400
    [Abstract] [Full Text] [Related]

  • 4. [A randomized, multicenter, active-controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with that of elcatonin in postmenopausal women with osteoporosis in China].
    Zhang XZ, Song LG, Wang B, Yang J, Li H, Xuan M, Lei T, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Shen J, Liu ZM, Li CJ, Wu TF, Xie HB, Tong JC.
    Zhonghua Nei Ke Za Zhi; 2010 Aug; 49(8):662-6. PubMed ID: 20979784
    [Abstract] [Full Text] [Related]

  • 5. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis.
    Cosman F, Eriksen EF, Recknor C, Miller PD, Guañabens N, Kasperk C, Papanastasiou P, Readie A, Rao H, Gasser JA, Bucci-Rechtweg C, Boonen S.
    J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967
    [Abstract] [Full Text] [Related]

  • 6. Effects of morning vs. evening teriparatide injection on bone mineral density and bone turnover markers in postmenopausal osteoporosis.
    Michalska D, Luchavova M, Zikan V, Raska I, Kubena AA, Stepan JJ.
    Osteoporos Int; 2012 Dec; 23(12):2885-91. PubMed ID: 22426952
    [Abstract] [Full Text] [Related]

  • 7. A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China.
    Zhang XZ, Wang B, Yang J, Xuan M, Song LG, Li H, Guo XH, Lü XF, Xue QY, Yang GY, Ji QH, Shen J, Liu ZM, Li CJ, Wu TF, Tong XC, Jia Y.
    Chin Med J (Engl); 2009 Dec 20; 122(24):2933-8. PubMed ID: 20137477
    [Abstract] [Full Text] [Related]

  • 8. Efficacy and safety of recombinant human parathyroid hormone (1-34) are similar to those of alendronate in the treatment of postmenopausal osteoporosis.
    Deng J, Feng Z, Li Y, Pan T, Li Q, Zhao C.
    Medicine (Baltimore); 2018 Nov 20; 97(47):e13341. PubMed ID: 30461654
    [Abstract] [Full Text] [Related]

  • 9. Profile of changes in bone turnover markers during once-weekly teriparatide administration for 24 weeks in postmenopausal women with osteoporosis.
    Sugimoto T, Nakamura T, Nakamura Y, Isogai Y, Shiraki M.
    Osteoporos Int; 2014 Mar 20; 25(3):1173-80. PubMed ID: 24108429
    [Abstract] [Full Text] [Related]

  • 10. Comparative effects of teriparatide and ibandronate on spine bone mineral density (BMD) and microarchitecture (TBS) in postmenopausal women with osteoporosis: a 2-year open-label study.
    Senn C, Günther B, Popp AW, Perrelet R, Hans D, Lippuner K.
    Osteoporos Int; 2014 Jul 20; 25(7):1945-51. PubMed ID: 24760244
    [Abstract] [Full Text] [Related]

  • 11. Effect of Teriparatide Treatment on Circulating Periostin and Its Relationship to Regulators of Bone Formation and BMD in Postmenopausal Women With Osteoporosis.
    Gossiel F, Scott JR, Paggiosi MA, Naylor KE, McCloskey EV, Peel NFA, Walsh JS, Eastell R.
    J Clin Endocrinol Metab; 2018 Apr 01; 103(4):1302-1309. PubMed ID: 29365099
    [Abstract] [Full Text] [Related]

  • 12. Evaluation of the efficacy, safety and pharmacokinetic profile of oral recombinant human parathyroid hormone [rhPTH(1-31)NH(2)] in postmenopausal women with osteoporosis.
    Henriksen K, Andersen JR, Riis BJ, Mehta N, Tavakkol R, Alexandersen P, Byrjalsen I, Valter I, Nedergaard BS, Teglbjaerg CS, Stern W, Sturmer A, Mitta S, Nino AJ, Fitzpatrick LA, Christiansen C, Karsdal MA.
    Bone; 2013 Mar 01; 53(1):160-6. PubMed ID: 23234813
    [Abstract] [Full Text] [Related]

  • 13. Serum sclerostin levels positively correlate with lumbar spinal bone mineral density in postmenopausal women--the six-month effect of risedronate and teriparatide.
    Polyzos SA, Anastasilakis AD, Bratengeier C, Woloszczuk W, Papatheodorou A, Terpos E.
    Osteoporos Int; 2012 Mar 01; 23(3):1171-6. PubMed ID: 21305266
    [Abstract] [Full Text] [Related]

  • 14. Early changes in biochemical markers of bone turnover and their relationship with bone mineral density changes after 24 months of treatment with teriparatide.
    Blumsohn A, Marin F, Nickelsen T, Brixen K, Sigurdsson G, González de la Vera J, Boonen S, Liu-Léage S, Barker C, Eastell R, EUROFORS Study Group.
    Osteoporos Int; 2011 Jun 01; 22(6):1935-46. PubMed ID: 20938767
    [Abstract] [Full Text] [Related]

  • 15. Pharmacokinetics of oral recombinant human parathyroid hormone [rhPTH(1-31)NH₂] in postmenopausal women with osteoporosis.
    Sturmer A, Mehta N, Giacchi J, Cagatay T, Tavakkol R, Mitta S, Fitzpatrick L, Wald J, Trang J, Stern W.
    Clin Pharmacokinet; 2013 Nov 01; 52(11):995-1004. PubMed ID: 23719683
    [Abstract] [Full Text] [Related]

  • 16. Bone turnover markers to explain changes in lumbar spine BMD with abaloparatide and teriparatide: results from ACTIVE.
    Eastell R, Mitlak BH, Wang Y, Hu M, Fitzpatrick LA, Black DM.
    Osteoporos Int; 2019 Mar 01; 30(3):667-673. PubMed ID: 30635696
    [Abstract] [Full Text] [Related]

  • 17. Comparison of the effect of 18-month daily teriparatide administration on patients with rheumatoid arthritis and postmenopausal osteoporosis patients.
    Ebina K, Hashimoto J, Shi K, Kashii M, Hirao M, Yoshikawa H.
    Osteoporos Int; 2014 Dec 01; 25(12):2755-65. PubMed ID: 25082556
    [Abstract] [Full Text] [Related]

  • 18. Differential effects of teriparatide on BMD after treatment with raloxifene or alendronate.
    Ettinger B, San Martin J, Crans G, Pavo I.
    J Bone Miner Res; 2004 May 01; 19(5):745-51. PubMed ID: 15068497
    [Abstract] [Full Text] [Related]

  • 19. Histomorphometric changes by teriparatide in alendronate-pretreated women with osteoporosis.
    Stepan JJ, Burr DB, Li J, Ma YL, Petto H, Sipos A, Dobnig H, Fahrleitner-Pammer A, Michalská D, Pavo I.
    Osteoporos Int; 2010 Dec 01; 21(12):2027-36. PubMed ID: 20135094
    [Abstract] [Full Text] [Related]

  • 20. Usefulness of daily teriparatide treatment in elderly patients over 80 years of age.
    Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Kono T, Sudo A.
    Osteoporos Int; 2016 May 01; 27(5):1869-74. PubMed ID: 26759334
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.